AbbVie to acquire Apogee for nearly $11B

AbbVie announced it will acquire Apogee Therapeutics for $10.9 billion in cash, valuing the company at $135.11 per share with a 50 percent premium. The deal focuses on Apogee’s lead drug, zumilokibart, which targets inflammatory conditions such as atopic dermatitis and asthma, and could offer a convenient dosing schedule. This acquisition strengthens AbbVie's position in the immunology field amid increased biotech mergers.

articleDetails.fontSize.sizeحجم النص

تنويه: هذا ملخص تم إنشاؤه بواسطة الذكاء الاصطناعي

عرض المقال بالكامل